CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that it has appointed James M. Anderson to its Board of
Directors effective immediately.
Mr. Anderson is President and Chief Executive Officer of Cincinnati
Children’s Hospital Medical Center. His appointment as President and CEO
in 1996 followed 20 years of service to the Cincinnati Children’s board
of trustees, including four years as chairman, as well as involvement on
the Executive, Finance, Investment and Compensation, Personnel and
Nominating committees. He was recently appointed chairman of the Board
of the Cincinnati Branch of the Federal Reserve Bank of Cleveland.
Prior to joining the staff of Cincinnati Children’s, Mr. Anderson was a
partner in the general corporate department at Taft, Stettinius &
Hollister for 24 years (1968-1977; 1982-96) and president of US
operations at Xomox Corporation (1977-82), a publicly traded
manufacturer of specialty process controls. His extensive civic
involvement includes service to the Dan Beard Council of the Boy Scouts
of America, Cincinnati Museum of Natural History and the College of Mt.
St. Joseph, Monarch Foundation. In May 2005, Mr. Anderson was honored
with the Human Relations Award presented by the Cincinnati chapter of
the American Jewish Committee, in recognition of his outstanding
professional contributions and his vision of a healthy Cincinnati
community.
William J. Motto, Executive Chairman of the Board said, “We are pleased
that Jim Anderson has accepted a seat on Meridian’s board. Jim has
extensive experience in health care management and business leadership
skills. His addition to our board strengthens Meridian’s ability to meet
and exceed the expectations of our shareholders. We welcome Jim to our
board and look forward to his input, ideas, and advice.”
Meridian is a fully integrated life science company that manufactures,
markets and distributes a broad range of innovative diagnostic test
kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics manufacturers
and biotech companies in more than 60 countries around the world. The
Company’s shares are traded through NASDAQ’s Global Select Market,
symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
John A. Kraeutler, CEO
or Melissa A.
Lueke, VP, CFO
513-271-3700
